Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Vera Therapeutics in a note issued to ...

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...

BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $72 from $62 and keeps an Outperform rating on the shares.

Ionis Pharmaceuticals is licensing out another experimental medicine, entering an agreement with Ono Pharmaceutical that ...

Rep. Andrew Garbarino (R., N.Y.), chairman of the House Homeland Security Committee's subcommittee on cybersecurity and infrastructure protection, said the change in administration and leadership at ...

Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...